Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (6)

Advertisement

Research Article Free access | 10.1172/JCI110571

Thyrotropin-releasing Hormone in the Pancreas and Brain of the Rat Is Regulated by Central Noradrenergic and Dopaminergic Pathways

Dennis Engler, David Chad, and Ivor M.D. Jackson

Division of Endocrinology, Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts 02111

Division of Endocrinology, Department of Neurology, Tufts University School of Medicine, Boston, Massachusetts 02111

New England Medical Center, Boston, Massachusetts 02111

Find articles by Engler, D. in: JCI | PubMed | Google Scholar

Division of Endocrinology, Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts 02111

Division of Endocrinology, Department of Neurology, Tufts University School of Medicine, Boston, Massachusetts 02111

New England Medical Center, Boston, Massachusetts 02111

Find articles by Chad, D. in: JCI | PubMed | Google Scholar

Division of Endocrinology, Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts 02111

Division of Endocrinology, Department of Neurology, Tufts University School of Medicine, Boston, Massachusetts 02111

New England Medical Center, Boston, Massachusetts 02111

Find articles by Jackson, I. in: JCI | PubMed | Google Scholar

Published June 1, 1982 - More info

Published in Volume 69, Issue 6 on June 1, 1982
J Clin Invest. 1982;69(6):1310–1320. https://doi.org/10.1172/JCI110571.
© 1982 The American Society for Clinical Investigation
Published June 1, 1982 - Version history
View PDF
Abstract

These studies have been undertaken to evaluate the role of the brain noradrenergic and dopaminergic pathways in the regulation of the secretion of thyrotropin-releasing hormone (TRH) in the central nervous system (CNS) and pancreas of the neonatal rat. When CNS stores of norepinephrine (NE) were selectively reduced by the subcutaneous administration of the dopamine-β-hydroxylase inhibitor FLA-63, TRH concentrations were significantly reduced throughout the brain. However, when CNS stores of both NE and dopamine (DA) were depleted by the subcutaneous administration of the tyrosine hydroxylase inhibitor α-methyl-ρ-tyrosine (α-MT), TRH concentrations in the brain were not significantly altered.

FLA-63 and α-MT did not significantly reduce pancreatic catecholamine concentrations, indicating that in the basal state, these agents predominantly deplete central catecholamine stores. Nevertheless, pancreatic TRH concentrations were markedly reduced by FLA-63, and this effect was significantly attenuated by the simultaneous intracerebroventricular (icv) administration of NE. In contrast to the effects of FLA-63, α-MT caused a significant increase in pancreatic TRH concentrations, and this effect was significantly lessened by icv DA. To determine whether the sympathetic nervous system might be one route by which these central effects are mediated, a chemical sympathectomy was induced with guanethidine. This treatment selectively reduced pancreatic concentrations of NE, and caused a marked increase in pancreatic TRH concentrations.

From these observations, we conclude the following: (a) within the central nervous system, both NE and DA are involved in regulating brain TRH secretion or biosynthesis, and the direction of action of these two neurotransmitters appears to be opposite; (b) pancreatic TRH secretion or biosynthesis is also controlled by the brain noradrenergic and dopaminergic systems, and the net effects of each of these pathways appears to be opposite; (c) at least one route by which impulses from the brain may travel and modulate pancreatic TRH secretion or biosynthesis is by the sympathetic nervous system.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1310
page 1310
icon of scanned page 1311
page 1311
icon of scanned page 1312
page 1312
icon of scanned page 1313
page 1313
icon of scanned page 1314
page 1314
icon of scanned page 1315
page 1315
icon of scanned page 1316
page 1316
icon of scanned page 1317
page 1317
icon of scanned page 1318
page 1318
icon of scanned page 1319
page 1319
icon of scanned page 1320
page 1320
Version history
  • Version 1 (June 1, 1982): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (6)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts